St. Jude Medical today reported sales and net earnings for the fourth quarter and year ended December 31, 2011. From the press release:
“Cardiac Rhythm Management
Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were$728 million for the fourth quarter of 2011, a 4 percent decrease compared to the fourth quarter of 2010. After adjusting for the impact of foreign currency, total CRM sales decreased 6 percent. Total CRM product sales for the full-year 2011 were $3.034 billion, essentially equal to 2010. On a currency neutral basis, total CRM sales declined 3 percent from the prior year.
Of that total, ICD product sales were$436 millionin the fourth quarter, a 5 percent decrease compared to the fourth quarter of 2010. ICD revenue growth decreased 6 percent after adjusting for the impact of foreign currency. ICD product sales for the full-year 2011 were$1.824 billion, flat when compared to 2010. On a constant currency basis, total ICD sales declined 2 percent from the prior year.
Fourth quarter pacemaker sales were$292 million, a 4 percent decrease compared to the fourth quarter of 2010. After adjusting for the impact of foreign currency, pacemaker sales decreased 5 percent. Total pacemaker sales for 2011 were$1.210 billion, approximately equal to pacemaker sales in 2010. On a constant currency basis, total pacemaker sales declined 5 percent from the prior year.”
…
“Neuromodulation
St. Jude Medical sales of neuromodulation products were $121 million in the fourth quarter of 2011, up 12 percent from the comparable quarter of 2010. On a constant currency basis, neuromodulation product sales increased 11 percent in the fourth quarter of 2011. Total neuromodulation product sales for 2011 were $419 million, up 10 percent over the prior year. On a constant currency basis, neuromodulation product sales increased 8 percent in 2011.”